Seizure‐free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials
Epilepsia · 2023-07 · 64 (7) · 1812-1820
DOI: 10.1111/epi.17618 ↗At a glance
Journal article in Epilepsia, published online on 2023-04-28. Written by Stéphane Auvin and 3 co-authors. Institution: Assistance Publique - Hôpitaux de Paris (APHP), Service de Neurologie Pédiatrique, EpiCARE European Reference Network (ERN) membre, Hôpital Robert De…. Major MEDLINE topics: Cannabidiol, Lennox Gastaut Syndrome. Cited 17 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Objective
In this post hoc analysis, we aimed to assess seizure‐free days as a potential new outcome measure to use in randomized placebo‐controlled trials (RCTs) of patients with Lennox–Gastaut syndrome (LGS).
Methods
In two phase 3 RCTs (GWPCARE3, GWPCARE4), eligible patients were randomized to receive plant‐derived highly purified cannabidiol (CBD; Epidiolex® in the USA; 100 mg/mL oral solution) at 10 mg/kg/day (CBD10; GWPCARE3 only), at 20 mg/kg/day (CBD20), or matched placebo. The treatment period comprised a 2‐week dose titration and a 12‐week maintenance period. This post hoc analysis evaluated the least‐squares (LS) mean changes from baseline and difference versus placebo in the number of drop or total seizure‐free days per 28 days during the treatment period or maintenance period alone. LS mean changes were estimated using an analysis of covariance model, with categorical age and baseline number of drop or total seizure‐free days as covariates, and treatment group as a fixed factor.
Results
A total of 396 patients were included in this post hoc analysis. During the 14‐week treatment period, LS mean changes from baseline in number of drop seizure‐free days per 28 days for patients receiving placebo ( n = 161), CBD10 ( n = 73), and CBD20 ( n = 162) were 2.81 (95% confidence interval [CI] = 1.75–3.88), 5.64 (95% CI = 4.08–7.20), and 6.45 (95% CI = 5.39–7.52), respectively. The LS mean differences in number of drop seizure‐free days versus placebo were 2.83 (95% CI = .98–4.68) for CBD10 and 3.64 (95% CI = 2.18–5.10) for CBD20. For total seizure‐free days, LS mean differences versus placebo were 2.63 (95% CI = .92–4.34) for CBD10 and 3.50 (95% CI = 2.16–4.85) for CBD20. The improvements from baseline in seizure‐free days during the maintenance period alone were similar to the entire treatment period. Significance Drop and total seizure‐free days represent potential new and clinically meaningful endpoints for future RCTs in patients with LGS.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Assistance Publique - Hôpitaux de Paris (APHP), Service de Neurologie Pédiatrique, EpiCARE European Reference Network (ERN) membre, Hôpital Robert Debré, Paris, France.
- Institut national de la santé et de la recherche médicale (INSERM) NeuroDiderot, Université Paris-Cité, Paris, France.
- Institut Universitaire de France (IUF), Paris, France.
- Jazz Pharmaceuticals, Inc., London, UK.
- Jazz Pharmaceuticals, Inc., Palo Alto, California, USA.
ORCID profiles: Stéphane Auvin
Cite
APA
Auvin, S., Nortvedt, C., Fuller, D. S., & Sahebkar, F. (2023). Seizure‐free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials. Epilepsia, 64(7), 1812-1820. https://doi.org/10.1111/epi.17618
Vancouver
Auvin S, Nortvedt C, Fuller DS, Sahebkar F. Seizure‐free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials. Epilepsia. 2023;64(7):1812-1820. doi:10.1111/epi.17618
BibTeX
@article{Auvin2023,
author = {Auvin, Stéphane and Nortvedt, Charlotte and Fuller, Douglas S and Sahebkar, Farhad},
title = {Seizure‐free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials},
journal = {Epilepsia},
year = {2023},
volume = {64},
number = {7},
pages = {1812--1820},
doi = {10.1111/epi.17618}
}
EUVIMED